Hypercalcaemia and increased serum interleukin‐6 levels induced by all‐trans retinoic acid in patients with multiple myeloma Journal Article


Authors: Niesvizky, R.; Siegel, D. S.; Busquets, X.; Nichols, G.; Muindi, J.; Warrell, R. P. Jr; Michaeli, J.
Article Title: Hypercalcaemia and increased serum interleukin‐6 levels induced by all‐trans retinoic acid in patients with multiple myeloma
Abstract: Summary. All‐trans retinoic acid (ATRA) inhibits human myeloma cell growth in vitro, presumably through the down‐regulation of interleukin 6 receptors (IL‐6R). Based on these and other studies, we initiated a phase II clinical trial using ATRA in patients with advanced refractory multiple myeloma (MM). We report that three out of six treated patients developed severe hypercalcaemia following administration of ATRA, which was accompanied by a significant rise in serum IL‐6 levels. Normal calcium levels were restored after the discontinuation of the drug and the administration of standard anti‐hypercalcaemic care. We suspect that down‐regulation of IL‐6R resulted in increased serum IL‐6 levels, leading to advanced bone resorption and hypercalcaemia. We conclude that the use of ATRA in patients with advanced MM is not warranted. 1995 Blackwell Publishing Ltd
Keywords: clinical article; clinical trial; multiple myeloma; phase 2 clinical trial; bisphosphonic acid derivative; hypercalcemia; interleukin 6; interleukin-6; retinoic acid; oral drug administration; blood level; tretinoin; human; priority journal; article; all‐trans retinoic acid; hypercalcaemia
Journal Title: British Journal of Haematology
Volume: 89
Issue: 1
ISSN: 0007-1048
Publisher: John Wiley & Sons  
Date Published: 1995-01-01
Start Page: 217
End Page: 218
Language: English
DOI: 10.1111/j.1365-2141.1995.tb08936.x
PUBMED: 7833269
PROVIDER: scopus
DOI/URL:
Notes: Article -- Export Date: 28 August 2018 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Raymond P Warrell
    175 Warrell
  2. Josephia R. F. Muindi
    25 Muindi